Skip to content

Remimazolam for Emergence Delirium Prevention in Patients Undergoing Rhinoseptoplasty, FESS or Septoplasty

Remimazolam for Emergence Delirium Prevention in Patients Undergoing Rhinoseptoplasty, FESS or Septoplasty

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06398275
Enrollment
80
Registered
2024-05-03
Start date
2024-03-06
Completion date
2024-12-31
Last updated
2024-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergence Delirium, Remimazolam, Rhinoplasty

Keywords

Remimazolam

Brief summary

The aim of this research is to confirm the effectiveness of remimazolam in preventing delirium during recovery from anesthesia in adult patients who have undergone one of the rhinological surgeries (septoplasty, rhinoseptoplasty or functional endoscopic sinus surgery). Patients aged 18-65, ASA classification I-II will be anesthetized with balanced anesthesia maintained with sevoflurane and will be randomized into two groups. The first group will receive remimazolam before anesthesia, while the second will receive normal saline solution. The main outcome of the study will be the presence/absence of delirium during anesthesia recovery, while the secondary outcome will be the postoperative pain level, the length of stay in the recovery room, the presence of unwanted events in the recovery room, and the presence of postoperative mood changes.

Interventions

Remimazolam 0.1 mg/kg intravenous injection

DRUGNaCl 0.9%

NaCl 0.9% 0.04 mL/kg

Sponsors

University Hospital of Split
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patients scheduled for rhinoplasty, rhinoseptoplasty or FESS * ASA I or II

Exclusion criteria

* pregnancy * patients treated with psychiatric medication (in the time of operation or 6 months prior to operation)

Design outcomes

Primary

MeasureTime frame
Richmond agitation sedation scaleImmediately after extubation and every five minutes after that for half hour

Countries

Croatia

Contacts

Primary ContactGrgur Prižmić
gregorio.prizmic@gmail.com+385994213808

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026